Search

Filter Options

Active Development

Reset

Delivery Type

Reset

Duration Type

Reset

Developer

Reset

User

Reset

Hormonal

Reset

Development Stage

Reset

Potential MPT

Reset

API

Reset
View by user and type (hormonal or non-hormonal)
Displaying 241 - 243 of 243
Alternative Name: Miglustat; N-butyldeoxynojirimycin (NB-DNJ)
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Oral
Developer: University of Washington, Oxford GlycoSciences
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: University of Nairobi
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
Alternative Name: β-human chorionic gonadotropin
User: Female
Hormonal: No
Duration Type: Short-acting
Developer: Talwar Research Foundation, Indian Council for Medical Research
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development

Pages

Displaying 41 - 50 of 70
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Merck
Development Stage: Prototype Development
Alternative Name: Metalloprotease
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University
Development Stage: Target Validation
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Microchips Biotech, Inc.
Development Stage: Prototype Development
Target
User: Male
Hormonal: No
Developer: University of Kansas Medical Center, University of Minnesota
Development Stage: Target Validation
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Washington University
Development Stage: Compound ID/Selection
Alternative Name: Lavax Vaginal Suppository
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other
Developer: Lavax
Development Stage: Lead Optimization
User: Male
Hormonal: No
Delivery Method: Oral
Developer: North Shore University Hospital in New York
Development Stage: Lead Optimization
Alternative Name: Nomegestrol acetate (NOMAC) vaginal ring
User: Female
Hormonal: Yes
Delivery Method: Vaginal Ring
Developer: Merck
Development Stage: Prototype Development
User: Female, Male
Duration Type: Short-acting, Pericoital
Delivery Method: Injectable, Vaginal, Other, Other
Development Stage: Lead Optimization
User: Male
Hormonal: Yes
Developer: University of Kansas Medical Center, University of Minnesota
Development Stage: Lead Optimization

Pages

Displaying 41 - 50 of 121
User: Male
Hormonal: No
Duration Type: Permanent, Short-acting
Delivery Method: Oral
Developer: WHO, South-to-South Cooperation in Reproductive Health
Development Stage: Phase I
Alternative Name: SARM C-6
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: GTx, Inc., Memphis, TN
Development Stage: Pre-clinical
Alternative Name: H2-GMZ
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: University of Kansas Medical Center, University of Minnesota
Development Stage: Pre-clinical
Alternative Name: Injectable Gestodene (GES) + Ethinyl Estradiol (EE)
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Peking University
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Stanford University
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: University of California San Diego
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: KYDES Pharmaceuticals, FHI 360
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: University of Tennessee Health Sciences Center
Development Stage: Pre-clinical
Alternative Name: Gendarussa
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: Airlangga University, Indopharma, FHI 360
Development Stage: Phase II
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: ContraMed, LLC
Development Stage: Phase II

Pages

Displaying 51 - 52 of 52
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Yantai Family Planning Medicine & Apparatus Co. Ltd., China
Development Stage: Marketed
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Yantai Family Planning Medicine & Apparatus Co. Ltd., China
Development Stage: Marketed

Pages

CSV